Recent posts
As a rule, getting a drug on the market turns a biotech startup from a buck bonfire into a cash cow—or at least a cash calf. But rules tend to get... Read more »
GTC Biotherapeutics (NASDAQ: GTCB), which bioengineers goats to secrete drugs in their milk, announced late yesterday that its groundbreaking medicine for a rare blood-clotting disorder cleared the main hurdle in... Read more »
Call it the 27-year-old startup: ImmunoGen, one of biotech’s oldest companies, has yet to get a drug on the market more than a quarter century after its formation in 1981.... Read more »
No doctors thwart the Reaper more often than cardiologists, who routinely pull heart-attack victims back from the brink with artery-opening procedures. But their god-like powers suddenly fade after coronary arteries are... Read more »
If you haven’t considered eating more fish or taking fish-oil pills by now, you’re probably very young, just in from Mars, or both. The case for the health benefits of omega-3... Read more »
The Great Bubble is dead and gone, but like Elvis it’s still occasionally sighted. Daytraders, for instance, could have sworn it was gyrating across their screens when WuXi PharmaTech recently went... Read more »
“Like does not like like that is obnoxious.” Poet Marianne Moore wasn’t thinking of autoimmune diseases when she penned this line but it memorably captures the strife behind them—when our immune... Read more »
Nothing robs pharma officials of more sleep than unexpected toxicity linked to one of their companies’ medicines. Recently they’ve lost more shuteye than ever as reports on cardiac risks of widely-used... Read more »
Oncology researchers are fond of saying that if you’re a mouse with cancer, they’ve found drugs that can cure you. Scientists at Cambridge-based Aveo Pharmaceuticals have even better news: They’ve developed... Read more »